Biosyent Inc (OTCPK:BIOYF)
$ 10.41 +0.015 (+0.14%) Market Cap: 117.33 Mil Enterprise Value: 113.35 Mil PE Ratio: 18.65 PB Ratio: 3.74 GF Score: 98/100

Q4 2021 Biosyent Inc Earnings Presentation Transcript

Mar 09, 2022 / NTS GMT
Release Date Price: $6.38 (+0.31%)
RenÃ;C. Goehrum
BioSyent Inc. - Chairman, CEO & President

© -

Hello, and welcome to the Q4 and fiscal year 2021 results presentation for BioSyent Inc. My name is René Goehrum, and I'm the President and CEO of the company.

I'm going to start today's presentation with a look at our revenue, EBITDA and net income after tax for the quarter ended December 31, 2021. As you can see, our sales reached just above $7.2 million in the quarter, which represented a 26% increase versus the year ago. Our EBITDA was just above $2.6 million, representing 136% increase to the year ago. And our net income after tax was just below $1.9 million, 182% of the year ago period.

So the fourth quarter represented our 46th consecutive profitable quarter, and that revenue growth was driven across the business. So our Canadian Pharma business was up 20%. Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot